Development and Characterization of Liposomal Tumor Necrosis Factor (Tnf)

References

• Pfreundschuh M G, Steinmetz H T, Tuschen R, Schenk V, Diehl V, Schaadt M. Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur. J. Cancer Clin. Oncol. 1989; 25: 379–388
   PubMedGoogle Scholar
• Bartsch H H, Pfizenmaier K, Schroeder M, Nagel G. A. Intratesional application of recombinant tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Clin. Oncol. 1989; 25: 287–291
   PubMedGoogle Scholar
• Kahn J O, Kaplan L D, Vollerding P A, Ziegler J L, Crowe S, Saks S R, Abrams D. I. Intralesional recombinant tumor necrosis factor-a for AIDS-associated Kaposi's sarcoma: A randomized, doubled-blind trial. J. Acq. Imm. Def. Syn. 1989; 2: 217–223
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Yoshida J, Mizuno M, Sugita K, Yoshida T. Effectiveness of tumor necrosis factor for malignant glioma; evaluation of its antitumor effects by CT and/or MRI. Biotherapy 1991; 5: 478–482
   Google Scholar
• Yamasaki T, Kikuchi H, Moritake K. Intraarterial immunotherapy with human natural TNF-a for recurrent malignant gliomas. 8th Intl. Lymphokine Workshop and the 4th Intl. Workshop on Cytokines, OsakaJapan, October, 17–21, 1993, Abstract 352
   Google Scholar
• Kaufman M, Schmid H., Raeth V, Grischke E M, Kempeni J, Schlick E, Bastert G. Therapy of ascites with tumor necrosis factor in ovarian cancer. Geburtshilfe und Frauenheilkunde. 1990; 50: 678–682
   PubMed Web of Science ®Google Scholar
• Mavligit G M, Zukiwski A A, Chamsangavej C, Carrasco C H, Wallace S, Gutterman J U. Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer. 1992; 69: 557–561
   PubMed Web of Science ®Google Scholar
• Fraker D. L., Alexander H. R. The use of tumor necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res. 1994; 4: 27–29
   PubMed Web of Science ®Google Scholar
• Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune F J. High-dose recombinat tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992; 10: 52–60
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont A M M, Schraffordt-Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-a), interferon-gamma (IFN-y) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1994; 4: 21–26
   PubMed Web of Science ®Google Scholar
• Vaglini M, Santinami M, Manzi R, et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-a), melphalan and interferon-gamma (IFN-y). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res. 1994; 4: 35–38
   PubMed Web of Science ®Google Scholar
• Hill S, Thomas J M. Low-dose tumour necrosis factor-alpha (TNF-a) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res. 1994; 4: 31–34
   PubMed Web of Science ®Google Scholar
• Debs R J, Duzgunes N, Brunette E N, Fendly B, Patton J R, Philip R. Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing antitumor necrosis factor antibodies. J. Immunol. 1989; 413: 1192–1197
   Google Scholar
• Debs R J, Fuchs H J, Philip R, Brunette E N, Duzgunes N, Shellito J E, Liggitt D, Patton J R. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor a in rats. Cancer Res. 1990; 50: 375–380
   PubMed Web of Science ®Google Scholar
• Allen T M, Chonn A. Large unilammelar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987; 223: 42–46
   PubMed Web of Science ®Google Scholar
• Gabizon A. A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992; 52: 891–896
   PubMed Web of Science ®Google Scholar
• Utsumi T, Hung M-C, Klostergaard J. Preparation and characterization of liposomal-lipophilic TNF. Cancer Res. 1991; 51: 3362–3366
   PubMed Web of Science ®Google Scholar
• Soma G-I, Tsuji Y, Tanabe Y, Noguchi K, Kitahara-Tanabe U, Gatanaga T, Inagawa H, Kawakima M, Mizuno D. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J. Biol. Resp. Mod. 1988; 7: 587–595, 1991
   PubMedGoogle Scholar
• Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G-I, Mizuno D. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-a in vivo. J. Biol. Resp. Mod. 1989; 8: 278–286
   PubMedGoogle Scholar
• Akimaru K, Auzenne A., Akimaru Y., Leroux M E, Utsumi T, Hayman A C, Soma G.-L, Klostergaard J. Formulation and characterization of liposomal-TNF-SAM2-. Clinical Cancer Res., submitted
   Google Scholar
• Lodato R F, Fcig B, Akimaru K, Soma G-I, Klostergaard J. Hemodynamic evaluation of recombinant human TNF-alpha, TNF-SAM2 and liposomal-TNF-SAM2 in an anesthesized dog model. J. Immunotherapy 1995; 17: 19–29
   Web of Science ®Google Scholar
• Kilbourn R G, Gross S S, Jubran A, Adams J, Griffith O W, Levi R, Lodato R F. N-Methyl-L-Arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA 1990; 87: 3629–3632
   PubMed Web of Science ®Google Scholar
• Lapidot Y, Rappoport S, Wolman Y. Use of esters of N-hydroxysuccinimide in the synthesis of N-acyl-amino acids. J. Lipid Res. 1976; 8: 142–145
   Google Scholar
• Utsumi T, Hung M-C, Klostergaard J. The role of amino functions in recombinant human tumor necrosis factor in expression of biological activity. Molec. Immunol. 1992; 29: 77–81
   PubMed Web of Science ®Google Scholar
• Oettgen H F, Old L. J. Tumor necrosis factor. Important Advances in Oncology, V T DeVita, S Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia 1987; 105–130, Chap. 7
   Google Scholar
• Blick M, Sherwin S A, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987; 47: 2986–2989
   PubMed Web of Science ®Google Scholar
• Klausner A. The TNF waiting game. Biotechnology 1987; 5: 335–341
   Google Scholar
• Taguchi T. A phase I study of recombinant human tumor necrosis factor. Jpn. J. Cancer Chemother. 1986; 13: 3491–3498
   PubMedGoogle Scholar
• Lodato R. F. The control of cardiac output. Cardiopulmonary Critical Care, 2nd ed., D R Dantzker. W. B. Saunders, Philadelphia 1991; 71–85, Chap. 4
   Google Scholar